Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
Department of Medical Oncology and Hematology, University of Lübeck, Lübeck, Germany.
Anticancer Res. 2020 Mar;40(3):1661-1664. doi: 10.21873/anticanres.14116.
BACKGROUND/AIM: Elderly patients with metastatic esophageal cancer may benefit from individualized therapies. A tool to predict the survival of such patients with brain metastases was created.
In 11 elderly patients (≥65 years) receiving whole-brain irradiation (WBI) for brain metastases from esophageal cancer, age, gender, performance status, number of brain metastases, metastases outside the brain, time between cancer diagnosis and WBI, and WBI regimen were evaluated for survival.
On univariate analyses, age ≥73 years (p=0.046) and time between diagnosis of esophageal cancer and WBI ≤6 months (p=0.046) were significantly associated with poorer survival. On multivariate analysis, both showed a trend. Based on these two factors, the following points were assigned: age ≤72 years=1 point, age ≥73 years=0 points; time between cancer diagnosis and WBI >6 months=1 point, and ≤6 months=0 points. Three prognostic groups were thus formed: 0, 1 and 2 points. Survival rates of these groups at 6 months were 0%, 0% and 40% (p=0.012), respectively.
This new tool allows estimation of survival and treatment individualization in elderly patients irradiated for brain metastases from esophageal cancer.
背景/目的：患有转移性食管癌的老年患者可能受益于个体化治疗。本研究旨在创建一种预测此类伴脑转移患者生存情况的工具。
在 11 名因食管癌脑转移而行全脑放疗（WBI）的老年患者（≥65 岁）中，评估年龄、性别、体力状况、脑转移数量、脑外转移、癌症诊断与 WBI 之间的时间以及 WBI 方案与生存之间的关系。
单因素分析显示，年龄≥73 岁（p=0.046）和食管癌诊断与 WBI 之间的时间≤6 个月（p=0.046）与生存较差显著相关。多因素分析显示，这两个因素均有趋势。根据这两个因素，分配以下分数：年龄≤72 岁=1 分，年龄≥73 岁=0 分；癌症诊断与 WBI 之间的时间>6 个月=1 分，≤6 个月=0 分。由此形成 3 个预后组：0、1 和 2 分。这些组在 6 个月时的生存率分别为 0%、0%和 40%（p=0.012）。
该新工具可用于估计因食管癌脑转移而行放疗的老年患者的生存情况并实现个体化治疗。
